Mercury Investment Group

Mercury Bio is a Santa Fe-based biotechnology company developing a next-generation drug delivery platform based on yeast-derived extracellular vesicles (yEVs). The company's technology aims to provide a more efficient, scalable, and targeted way to deliver RNA, proteins, and small molecules compared to traditional lipid nanoparticles (LNPs). Their platform, which leverages the natural communication systems of yeast, is designed to be low-cost and highly customizable for various therapeutic areas, including oncology and infectious diseases. Mercury Bio's approach focuses on overcoming the limitations of current delivery systems, such as toxicity and limited tissue targeting, by utilizing the inherent biocompatibility of yeast-derived vesicles.